Liquidia Corporation

08/19/2024 | Press release | Distributed by Public on 08/19/2024 04:15

U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.